Vascular disrupting agents (vdas) in anticancer therapy

Current Clinical Pharmacology

Volumn 5, Issue 3, 2010, Pages 178-185

  Daenen, Laura G M ^a   Roodhart, Jeanine M L ^a   Shaked, Yuval ^b   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anti cancer therapy; Combination therapy; Tumor repopulation; Vascular disrupting agents; Vascular shutdown

Indexed keywords

3 BENZYLIDENE 6 [(5 TERT BUTYL 1H IMIDAZOL 4 YL)METHYLENE] 2,5 PIPERAZINEDIONE; BEVACIZUMAB; BNC 105P; CA 4P; CA4P; CARBOPLATIN; CKD 516; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; CYT 997; DENIBULIN; EPC 2407; HYPOXIA INDUCIBLE FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MPC 6827; MYOSIN LIGHT CHAIN; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SOBLIDOTIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THYROID CARCINOMA; TUMOR BLOOD FLOW; TUMOR GROWTH; UPREGULATION;

ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 78649250212     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410791498815     Document Type: Article

References (104)

1. Kerbel RS.Tumor angiogenesis, N Engl J Med 2008; 358(19):2039-49
2. Auerbach W, Auerbach R. Angiogenesis inhibition: a review, Pharmacol Ther 1994; 63(3): 265-311.
3. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993, 66(783): 181-96.
4. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anti-cancer Res 1999; 19(1A): 189-95.
5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57(10): 1829-34.
6. Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res 1997; 9(2): 55-60.
7. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer Suppl 1996; 27: S86-S88.
8. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27(4): 482-7.
9. Boyland E, Boyland ME. Studies in tissue metabolism: The action of colchicine and B. typhosus extract. Biochem J 1937; 31(3): 454-60.
10. McGown AT, Fox BW. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des 1989; 3(4): 249-54.
11. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, GarciaKendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45(2): 209-11.
12. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 1987; 50(1): 119-31.
13. Pettit GR, Temple C, Jr., Narayanan VL, et al. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 1995; 10(4): 299-309.
14. Pettit GR, Lippert JW, III. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 2000; 15(3): 203-16.
15. Hua J, Sheng Y, Pinney KG, et al.Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate, Anticancer Res 2003, 23(2B):1433-40.
16. Thorpe PE, Chaplin DJ, Blakey DC The first international conference on vascular targeting: meeting overview, Cancer Res 2003, 63(5):1144-7.
17. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62(12): 3408-16.
18. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21(15): 2815-22.
19. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21(23): 4428-38.
20. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000; 20(1A): 229-33.
21. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66(24): 11520-39.
22. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998; 42(4): 899-903.
23. Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 2004; 60(4): 1233-40.
24. Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pa-thologies. Int J Exp Pathol 2009; 90(3): 284-94.
25. Tolcher AW, Forero L, Celio P, et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular analogue, administered weekly for 3 weeks every 28 days. Proc Am Soc Clin Oncol 2003; 22: 834.
26. Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006, 24(10):1491-8.
27. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007; 96(8): 1159-65.
28. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999; 59(7): 1626-34.
29. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61(17): 6413-22.
30. Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001; 21(1A): 93-102.
31. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999; 81(8): 1318-27.
32. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99(6): 2060-9.
33. Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelialcadherin signaling. J Clin Invest 2005; 115(11): 2992-3006.
34. Petit I, Karajannis MA, Vincent L, et al The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death, Blood 2008; 111(4):1951-61.
35. Folkes LK, Christlieb M, Madej E, Stratford MR, Wardman P Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to en-hance oxidative stress via free radicals. Chem Res Toxicol 2007;20(12):1885-94.
36. Wang X, Martindale JL, Liu Y, Holbrook NJ The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival, Biochem J 1998; 333 (Pt 2):291-300.
37. Houle F, Huot J. Dysregulation of the endothelial cellular response to oxidative stress in cancer. Mol Carcinog 2006; 45(6): 362-7.
38. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5(6): 423-35.
39. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003; 4(6): 446-56.
40. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002; 8(6): 1974-83.
41. Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 2002; 21(4): 717-26.
42. Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 2000; 83(6): 811-6.
43. Brooks AC, Kanthou C, Cook IH, et al The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro, Anticancer Res 2003;23(4):3199-206.
44. Ahmed B, van Eijk LI, Bouma-Ter Steege JC, et al. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer 2003;105(1):20-5.
45. Griggs J, Hesketh R, Smith GA, et al. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br J Cancer 2001; 84(6): 832-5.
46. Pasquier E, Honore S, Braguer D. Microtubule-targeting agents in angiogenesis: where do we stand?, Drug Resist Updat 2006;9(1-2):74-86.
47. Kanthou C, Greco O, Stratford A, et al. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death, Am J Pathol 2004;165(4):1401-11.
48. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY, Smulson ME. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998; 58(20): 4510-4.
49. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60(5): 1388-93.
50. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 1991; 51(1): 265-73.
51. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003; 163(5): 1801-15.
52. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156(4): 1363-80.
53. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60(5): 1388-93.
54. Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al Katib AM. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines, Anticancer Drugs 2000; 11(5):385-92.
55. Nabha SM, Mohammad RM, Wall NR, et al Evaluation of combretastatin A4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy, Anticancer Drugs 2001;12(1):57-63.
56. Vitale I, Antoccia A, Cenciarelli C, et al. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis 2007; 12(1): 155-66.
57. el Zayat AA, Degen D, Drabek S, Clark GM, Pettit GR, Von Hoff DD. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs 1993; 4(1): 19-25.
58. Dachs GU, Steele AJ, Coralli C, et al. Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 2006; 6: 280.
59. Lin HL, Chiou SH, Wu CW, et al. Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells. J Pharmacol Exp Ther 2007; 323(1): 365-73.
60. Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002; 12(12): 1063-70.
61. Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model, J Clin Endocrinol Metab 2007;92(8):2902-9.
62. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009; 19(3): 233-40.
63. Hill SA, Chaplin DJ, Lewis G, Tozer GM. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer 2002; 102(1): 70-4.
64. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure, Nat Rev Cancer 2005;5(7):516-25.
65. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284(5422): 1994-8.
66. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease, Cancer 2004;100(12):2491-9.
67. Sheng Y, Hua J, Pinney KG, et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 2004; 111(4): 604-10.
68. Shaked Y, Tang T, Woloszynek J, et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents, Cancer Res 2009;69(19):7524-8.
69. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359(6398): 843-5.
70. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008; 28(4B): 2027-31.
71. Shi W, Siemann DW. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 2005; 19(6): 1045-50.
72. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors, Science 2006; 313(5794):1785-7.
73. Farace F, Massard C, Borghi E, Bidart JM, Soria JC. Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann Oncol 2007; 18(8): 1421-2.
74. Nathan PD, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors, J Clin Oncol 2008;26:Abstract 3550.
75. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105(8): 1045-7.
76. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106(9): 3058-61.
77. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63(15): 4342-6.
78. Daenen LG, Shaked Y, Man S, et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 2009; 8(10): 2872-81.
79. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8(3): 211-26.
80. Jin DK, Shido K, Kopp HG, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12(5): 557-67.
81. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13(7): 265-70.
82. Ribatti D, Nico B, Crivellato E, Vacca A. Macrophages and tumor angiogenesis. Leukemia 2007; 21(10): 2085-9.
83. Nelkin BD, Ball DW. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 2001; 8(1): 157-60.
84. Morinaga Y, Suga Y, Ehara S, Harada K, Nihei Y, Suzuki M. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 2003; 94(2): 200-4.
85. Giavazzi R, Bani MR, Taraboletti G. Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds, Cancer Metastasis Rev 2007;26(3-4):481-8.
86. Martinelli M, Bonezzi K, Riccardi E, et al. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007; 97(7): 888-94.
87. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008; 14(3): 263-73.
88. Horsman MR, Murata R, Breidahl T, et al. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 2000; 476: 311-23.
89. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10(2): 415-27.
90. Anderson H, Price P, Blomley M, Leach MO, Workman P. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques, Br J Cancer 2001;85(8):1085-93.
91. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated bydynamic magnetic resonance imaging. J Clin Oncol 2003; 21(15): 2831-42
92. Anderson H, Yap J, Price P Measurement of tumour and normal tissue (NT) perfusion by positron emission tomography (PET) in the evaluation of antivascular therapy: results in the Phase I study of combretastatin A4 phosphate (CA4P), Proc Am Soc Clin Oncol 2000;(19):695.
93. Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS. Highfrequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 2002; 62(22): 6371-5.
94. Maxwell RJ, Nielsen FU, Breidahl T, Stodkilde-Jorgensen H, Horsman MR. Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI. Int J Radiat Oncol Biol Phys 1998; 42(4): 891-4.
95. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998; 77(11): 1761-7.
96. Pedley RB, El Emir E, Flynn AA, et al. Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys 2002; 54(5): 1524-31.
97. Tozer GM, Prise VE, Lewis G, Xie S, Wilson I, Hill SA. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses. Clin Cancer Res 2009; 15(11): 3781-90.
98. Hokland SL, Horsman MR. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization. Int J Hyperthermia 2007; 23(7): 599-606.
99. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3(10): 721-32.
100. Koh MY, Spivak-Kroizman TR, Powis G. Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin Cancer Res 2009; 15(19): 5945-6.
101. Harris AL. Hypoxia a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2(1): 38-47.
102. Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol 2007; 435: 297-321.
103. El Emir E, Boxer GM, Petrie IA, et al. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer 2005; 41(5): 799-806.
104. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4(6): 437-47.